First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition ... affects older people in the 60 to 80 age bracket. Dupixent (dupilumab) achieved a five-fold greater sustained ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

Dupixent (dupilumab ... further into areas like chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic hives, and allergies. In trials, tralokinumab ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...